The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy

Immune checkpoint inhibitors (ICIs), such as PD-1/PD-L1 antibodies (Abs) and anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) Abs, are effective for patients with various cancers. However, low response rates to ICI monotherapies and even hyperprogressive disease (HPD) have limited the clinical applica...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xueping, Wang, Fang, Zhong, Mengjun, Yarden, Yosef, Fu, Liwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195736/
https://www.ncbi.nlm.nih.gov/pubmed/32359357
http://dx.doi.org/10.1186/s12943-020-01200-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195736/
https://www.ncbi.nlm.nih.gov/pubmed/32359357
http://dx.doi.org/10.1186/s12943-020-01200-x

Ejemplares similares